U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C6H12O6
Molecular Weight 180.1559
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of D-PSICOSE

SMILES

OC[C@@H](O)[C@@H](O)[C@@H](O)C(=O)CO

InChI

InChIKey=BJHIKXHVCXFQLS-PUFIMZNGSA-N
InChI=1S/C6H12O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3,5-9,11-12H,1-2H2/t3-,5-,6+/m1/s1

HIDE SMILES / InChI

Molecular Formula C6H12O6
Molecular Weight 180.1559
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

D-Psicose (akaD-allulose) is a low energy monosaccharide found throughout nature in small quantities. t is a c-3 epimer of D-fructose and has 50% the sweetness of sucrose. Possible health benefits include improved insulin resistance, antioxidant enhancement and formation, and hypoglycemic controls. The use US-FDA lists psicose as generally recognized as safe (GRAS) and has approved its use as a food additive in a wide variety of products. Psicose is not generally metabolized and does not raise blood sugar levels above baseline after consumption. In addition, to use as a low-calorie sweetener, psicose has also been formally investigated as a dietary supplement to control obesity and pre-diabetic insulin insensitivities. Furthermore, D-psicose has shown the ability to inhibit the proliferation of ovarian cancer cells in vitro.

Approval Year

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown
Primary
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Over 5 visits Healthy volunteers and volunteers with impaired fasting glucose consumed 1 of 5 beverages with 50 g sucrose and varying levels of D-psicose (0,2.5, 5, 7.5 and 10 g). Beverages were presented in a random order and the subject and investigator were blind to the composition of the beverage. Subjects maintained 24-hour dietary records prior to each visit and abstained from consuming any calories for 8 hours prior to the visit. Venous blood samples were collected prior to consuming the beverage and at 30, 60, 90, and 10 min after.
Route of Administration: Oral
In Vitro Use Guide
Human ovarian adenocarcinoma cells (OVACAT-3) were maintained at 37 deg-C under an atmosphere of 5% CO2 in RPMI 1640 medium and supplemented with 10% fetal calf serum, 10 micro-g/mL insulin, 100 IU/mL penicillin, and 100 micro-g/mL streptomycin. Cell growth assay was initiated when the OVCAR-3 cells were in the logarithmic growth phase. Cells were seeded onto a 96-well plate with medium and cultured for 24 hours. Culture medium was refreshed including 50 mM of D-psicose. After 1 - 5 days, 10 micro L of MTT solution was added to each well and the plates incubated another 4 hours at 37 deg-C. The dose-dependent effect was further investigated by adding different concentrations of D-psicose (1, 5, 10, 20, 50 mM). The final MTT assay was performed after 1- 3 days. The inhibitory effect of D-allose on cancer cell proliferation was shown from day 1 and became more significant at day 5, in contrast to untreated cells. Furthermore, studies on the concentration effect of D-allose indicated that D-allose inhibits cells proliferation in a dose-dependent manner
Substance Class Chemical
Record UNII
QCC18LNG3E
Record Status Validated (UNII)
Record Version